Shooting for the Moon or Flying Too Near the Sun? Crossing the Value Rubicon in Precision Cancer Care

Mark Lawler, Declan French, Raymond Henderson, Ajay Aggarwal, Richard Sullivan

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)


In his last two State of the Union addresses, President Barack Obama has focused on the need to deliver innovative solutions to improve human health, through the Precision Medicine Initiative in 2015 and the recently announced Cancer Moonshot in 2016. Precision cancer care has delivered clear patient benefit, but even for high-impact medicines such as imatinib mesylate (Glivec) in chronic myeloid leukaemia, the excitement at the success of this practice-changing clinical intervention has been somewhat tempered by the escalating price of this 'poster child' for precision cancer medicine (PCM). Recent studies on the costs of cancer drugs have revealed significant price differentials, which are a major causative factor behind disparities in the access to new generations of immunological and molecularly targeted agents. In this perspective, we will discuss the benefits of PCM to modern cancer control, but also emphasise how increasing costs are rendering the current approaches to integrating the paradigm of PCM unsustainable. Despite the ever increasing pressure on cancer and health care budgets, innovation will and must continue. Value-based frameworks offer one of the most rational approaches for policymakers committed to improving cancer outcomes through a public health approach.

Original languageEnglish
Pages (from-to)132-6
Number of pages5
JournalPublic health genomics
Issue number3
Early online date01 Jun 2016
Publication statusPublished - Jun 2016


Dive into the research topics of 'Shooting for the Moon or Flying Too Near the Sun? Crossing the Value Rubicon in Precision Cancer Care'. Together they form a unique fingerprint.

Cite this